EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms

Parastou Tizro iD, Eric Vail iD, Manoj Sapkota iD, Matthew G Gayhart iD, Celeste C Eno iD

Cancers · 31.07.2026 · 18 (15) · 2458

DOI: 10.3390/cancers18152458 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 31.07.2026. Verfasst von Parastou Tizro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Myeloproliferative neoplasms (MPNs) are chronic myeloid malignancies characterized by substantial genetic heterogeneity. Although routine molecular evaluation focuses on canonical driver alterations (BCR::ABL1, JAK2, CALR, and MPL), additional somatic mutations have important diagnostic and prognostic implications.

Methods

We retrospectively analyzed 1209 consecutive patients who underwent peripheral blood next-generation sequencing (NGS) for suspected or established MPNs using a comprehensive 75-gene DNA/RNA panel.

Results

Canonical driver alterations were identified in 141 patients, while 1068 were driver-negative. Retrospective analysis demonstrated that 251 patients (21%) harbored at least one additional pathogenic or likely pathogenic mutation that was not routinely reported. Among driver-positive patients, 57 of 141 (40%) carried clinically relevant co-mutations, including high-molecular-risk genes such as ASXL1, TP53, SRSF2, SF3B1, RUNX1, U2AF1, and IDH2. Furthermore, 194 of 1068 (18%) driver-negative patients harbored additional pathogenic mutations, several of which supported clonal hematopoiesis or alternative myeloid neoplasms. Peripheral blood and bone marrow molecular findings demonstrated high concordance (R2 = 0.87).

Conclusions

These findings indicate that comprehensive NGS performed at the time of initial evaluation provides clinically relevant genomic information beyond canonical driver mutations, improves disease classification and risk stratification, and may facilitate earlier diagnosis and personalized management of patients with suspected MPNs.

Schlagwörter

Stichwörter der Autor:innen

CALRHMRJAK2MPLMPNmutationprognosis

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8723 Alden Drive, SSB-362, Los Angeles, CA 90048, USA.
  • Department of Horticulture, University of Kentucky, Lexington, KY 40546, USA.

ORCID-Profile: Parastou Tizro, Eric Vail, Manoj Sapkota, Matthew G Gayhart, Celeste C Eno

Zitieren

APA

Tizro, P., Vail, E., Sapkota, M., Gayhart, M. G., & Eno, C. C. (2026). Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms. Cancers, 18(15), 2458. https://doi.org/10.3390/cancers18152458

Vancouver

Tizro P, Vail E, Sapkota M, Gayhart MG, Eno CC. Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms. Cancers. 2026;18(15):2458. doi:10.3390/cancers18152458

BibTeX
@article{Tizro2026,
  author = {Tizro, Parastou and Vail, Eric and Sapkota, Manoj and Gayhart, Matthew G and Eno, Celeste C},
  title = {Unmasking Additional Mutations: A Single Institution Study in Myeloproliferative Neoplasms},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2458},
  doi = {10.3390/cancers18152458}
}
Kostenlos starten →